Eli LilliFirst-quarter results missed expectations on Thursday, but the drug company raised its full-year guidance.
Before releasing the results, the company also reported positive data on its weight-loss drug, Tirzepatide.
related investment news
Eli Lilly’s stock closed nearly 4% higher at $390.35 per share.
The company’s revenue declined 11% from the year-ago quarter, driven by a $1.5 billion decline in sales of its Covid-19 antibodies. Lilly reported sales of $6.96 billion for the quarter, slightly beating analysts’ expectations, but sales declined from $7.81 billion in the year-ago quarter.
The company posted adjusted earnings of $1.62 per share, falling short of analysts’ expectations of $1.73 per share for the quarter.
Here’s how the company compares to analyst estimates compiled by Refinitiv:
- Adjusted earnings: $1.62 per share versus $1.73 per share expected
- Revenue: $6.96 billion versus $6.86 billion expected
The company reported net income of $1.3 billion, or $1.49 per share, for the quarter, down 29% from the first quarter of 2022.
Eli Lilly raised its forecast for the year largely due to the US dollar’s weakening against major currencies. The company expects revenue of between $31.2 billion and $31.7 billion compared to previous guidance of $30.3 billion to $30.8 billion.
The company raised its adjusted earnings guidance to between $8.65 and $8.85 per share for the year, up from $8.35 to $8.55.
Lilly also released data on its weight-loss drug Tirzepatide on Thursday morning ahead of the win. Patients who were overweight and had type 2 diabetes lost an average of between 30 and 34 pounds, depending on the dose, compared with 7 pounds in the placebo group.
Lilly plans to complete its application for Food and Drug Administration approval in the coming weeks.
CNBC Health & Science
Read CNBC’s latest global health coverage:
The FDA approved tirzepatide under the brand name Mounjaro in May 2022 for the treatment of adults with type 2 diabetes. Lilly’s Mounjaro revenue was approximately $567 million in the first quarter.
Sales for several of Lilly’s key products increased year over year. Revenue for Trulicity, Lilly’s weekly injectable for type 2 diabetes, was $1.98 billion for the quarter, up 14% from $1.74 billion for the same period last year.
Sales of Verzenio, Lilly’s breast cancer pill, rose 60% to $751 million, compared to $469 million in the first quarter of 2022.
And sales of Jardiance, a pill that lowers blood sugar in patients with type 2 diabetes, rose 38% to $578 million, compared with $419 million for the same period last year.
Correction: Lilly’s revenue in Mounjaro was about $567 million in the first quarter. A previous version incorrectly stated the figure.
Comments are closed.